293 related articles for article (PubMed ID: 12814677)
21. [Impact of immunochemotherapy on survival of patients with metastatic renal cell carcinoma. A retrospective study comparing interferon-alpha-2a/vinblastine versus interferon-alpha-2a/interleukin-2/5-fluorouracil].
May M; Helke C; Bock M; Hoschke B
Urologe A; 2004 Sep; 43(9):1111-9. PubMed ID: 15232686
[TBL] [Abstract][Full Text] [Related]
22. [Interleukin 2 based ambulatory therapy of metastatic renal cell carcinoma].
Atzpodien J; Kirchner H; Poliwoda H
Med Klin (Munich); 1996 Apr; 91 Suppl 3():38-43. PubMed ID: 8692118
[TBL] [Abstract][Full Text] [Related]
23. Immunotherapy for advanced renal cell cancer.
Coppin C; Porzsolt F; Kumpf J; Coldman A; Wilt T
Cochrane Database Syst Rev; 2000; (3):CD001425. PubMed ID: 10908496
[TBL] [Abstract][Full Text] [Related]
24. Metastatic renal cell carcinoma: systemic treatment.
Abi-Aad AS; deKernion JB
Acta Urol Belg; 1996 May; 64(2):3-8. PubMed ID: 8701805
[No Abstract] [Full Text] [Related]
25. [Immunotherapy of renal cell carcinoma. With special emphasis on therapy of the elderly patient].
Heinzer H; Huland E; Huland H
Urologe A; 2003 Nov; 42(11):1450-2. PubMed ID: 14624342
[TBL] [Abstract][Full Text] [Related]
26. Interleukin-2-based therapy for metastatic renal cell cancer: the Cytokine Working Group experience, 1989-1997.
Dutcher JP; Atkins M; Fisher R; Weiss G; Margolin K; Aronson F; Sosman J; Lotze M; Gordon M; Logan T; Mier J
Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S73-8. PubMed ID: 9457399
[TBL] [Abstract][Full Text] [Related]
27. Long-term follow-up of patients with metastatic renal cell carcinoma treated with intravenous recombinant interleukin-2 in Europe.
Negrier S; Maral J; Drevon M; Vinke J; Escudier B; Philip T
Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S93-8. PubMed ID: 10685667
[TBL] [Abstract][Full Text] [Related]
28. Interferon-alpha-2a with or without 13-cis retinoic acid in patients with progressive, measurable metastatic renal cell carcinoma.
Fosså SD; Mickisch GH; De Mulder PH; Horenblas S; van Oosterom AT; van Poppel H; Fey M; Croles JJ; de Prijck L; Van Glabbeke M
Cancer; 2004 Aug; 101(3):533-40. PubMed ID: 15274066
[TBL] [Abstract][Full Text] [Related]
29. The role of interferon and interleukin-2 in the immunotherapeutic approach to renal cell carcinoma.
Figlin RA; Abi-Aad AS; Belldegrun A; deKernion JB
Semin Oncol; 1991 Oct; 18(5 Suppl 7):102-7. PubMed ID: 1719641
[TBL] [Abstract][Full Text] [Related]
30. The timing of immunotherapy and nephrectomy in multimodality treatment of metastatic renal cell carcinoma.
Bex A; Horenblas S; de Gast GC
Technol Cancer Res Treat; 2003 Jun; 2(3):205-10. PubMed ID: 12779351
[TBL] [Abstract][Full Text] [Related]
31. Immunotherapy for renal cell carcinoma.
Rosenblatt J; McDermott DF
Hematol Oncol Clin North Am; 2011 Aug; 25(4):793-812. PubMed ID: 21763968
[TBL] [Abstract][Full Text] [Related]
32. Intratumoural and peripheral blood lymphocyte subsets in patients with metastatic renal cell carcinoma undergoing interleukin-2 based immunotherapy: association to objective response and survival.
Donskov F; Bennedsgaard KM; Von Der Maase H; Marcussen N; Fisker R; Jensen JJ; Naredi P; Hokland M
Br J Cancer; 2002 Jul; 87(2):194-201. PubMed ID: 12107842
[TBL] [Abstract][Full Text] [Related]
33. A randomized phase II trial comparing two different sequence combinations of autologous vaccine and human recombinant interferon gamma and human recombinant interferon alpha2B therapy in patients with metastatic renal cell carcinoma: clinical outcome and analysis of immunological parameters.
Schwaab T; Heaney JA; Schned AR; Harris RD; Cole BF; Noelle RJ; Phillips DM; Stempkowski L; Ernstoff MS
J Urol; 2000 Apr; 163(4):1322-7. PubMed ID: 10737537
[TBL] [Abstract][Full Text] [Related]
34. Interleukin-2-based immunotherapy for the treatment of metastatic renal cell carcinoma: an analysis of 203 consecutively treated patients.
Figlin R; Gitlitz B; Franklin J; Dorey F; Moldawer N; Rausch J; deKernion J; Belldegrun A
Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S92-7. PubMed ID: 9457402
[TBL] [Abstract][Full Text] [Related]
35. Treatments, Outcomes, and Validity of Prognostic Scores in Patients With Sarcomatoid Renal Cell Carcinoma: A 20-Year Single-Institution Experience.
Korenbaum C; Pierard L; Thiéry A; Story F; Lindner V; Lang H; Kurtz JE; Barthélémy P
Clin Genitourin Cancer; 2018 Jun; 16(3):e577-e586. PubMed ID: 29395949
[TBL] [Abstract][Full Text] [Related]
36. Prognostic factors of the clinical response to subcutaneous immunotherapy with interleukin-2 alone in patients with metastatic renal cell carcinoma.
Lissoni P; Barni S; Ardizzoia A; Crispino S; Paolorossi F; Andres M; Scardino E; Tancini G
Oncology; 1994; 51(1):59-62. PubMed ID: 8265104
[TBL] [Abstract][Full Text] [Related]
37. Rational selection of a control arm for randomised trials in metastatic renal cell carcinoma.
Mickisch GH
Eur Urol; 2003 Jun; 43(6):670-9. PubMed ID: 12767369
[TBL] [Abstract][Full Text] [Related]
38. Current clinical practice of induction and maintenance immunotherapy for metastatic renal cell carcinoma.
Little B; Young M; Ho KJ
Int J Clin Pract; 2002; 56(1):36-9. PubMed ID: 11831831
[TBL] [Abstract][Full Text] [Related]
39. Human renal carcinoma line transfected with interleukin-2 and/or interferon alpha gene(s): implications for live cancer vaccines.
Belldegrun A; Tso CL; Sakata T; Duckett T; Brunda MJ; Barsky SH; Chai J; Kaboo R; Lavey RS; McBride WH
J Natl Cancer Inst; 1993 Feb; 85(3):207-16. PubMed ID: 8423625
[TBL] [Abstract][Full Text] [Related]
40. Patterns of relapse and response to retreatment in patients with metastatic melanoma or renal cell carcinoma who responded to interleukin-2-based immunotherapy.
Lee DS; White DE; Hurst R; Rosenberg SA; Yang JC
Cancer J Sci Am; 1998; 4(2):86-93. PubMed ID: 9532410
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
